| Cost-effectiveness of treating influenzalike illness with oseltamivir in the United States SE Talbird, AJ Brogan, AP Winiarski, B Sander American Journal of Health-System Pharmacy 66 (5), 469-480, 2009 | 40 | 2009 |
| Cost-effectiveness of telaprevir combination therapy for chronic hepatitis C AJ Brogan, SE Talbird, JR Thompson, JD Miller, J Rubin, B Deniz PLoS One 9 (3), e90295, 2014 | 33 | 2014 |
| Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection J Mauskopf, AJ Brogan, SE Talbird, S Martin Aids 26 (3), 355-364, 2012 | 28 | 2012 |
| Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries SE Talbird, TN Taylor, S Knoll, CR Frostad, SG Martí Vaccine 28, G23-G29, 2010 | 28 | 2010 |
| Impact of population aging on the burden of vaccine-preventable diseases among older adults in the United States SE Talbird, EM La, J Carrico, S Poston, JE Poirrier, JK DeMartino, ... Human Vaccines & Immunotherapeutics 17 (2), 332-343, 2021 | 27 | 2021 |
| Cost-effectiveness of seasonal quadrivalent versus trivalent influenza vaccination in the United States: A dynamic transmission modeling approach AJ Brogan, SE Talbird, AE Davis, EW Thommes, G Meier Human Vaccines & Immunotherapeutics 13 (3), 533-542, 2017 | 27 | 2017 |
| Modelling the effect of conjugate vaccines in pneumococcal disease: cohort or population models? B Standaert, N Demarteau, S Talbird, J Mauskopf Vaccine 28, G30-G38, 2010 | 22 | 2010 |
| Understanding the role of exogenous boosting in modeling varicella vaccination SE Talbird, EM La, J Mauskopf, A Altland, V Daniels, LJ Wolfson Expert Review of Vaccines 17 (11), 1021-1035, 2018 | 21 | 2018 |
| Impact of tetanus, diphtheria, and acellular pertussis (Tdap) vaccine use in wound management on health care costs and pertussis cases SE Talbird, J Graham, J Mauskopf, C Masseria, G Krishnarajah Journal of managed care & specialty pharmacy 21 (1), 88-99, 2015 | 21 | 2015 |
| Impact of routine childhood immunization in reducing vaccine-preventable diseases in the United States SE Talbird, J Carrico, EM La, C Carias, GS Marshall, CS Roberts, ... Pediatrics 150 (3), e2021056013, 2022 | 20 | 2022 |
| Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United States WL Herring, Y Zhang, V Shinde, J Stoddard, SE Talbird, B Rosen Vaccine 40 (3), 483-493, 2022 | 20 | 2022 |
| Residual economic burden of Streptococcus pneumoniae-and nontypeable Haemophilus influenzae-associated disease following vaccination with PCV-7: a multicountry analysis SE Talbird, TN Taylor, J Caporale, AS Ismaila, J Gomez Vaccine 28, G14-G22, 2010 | 20 | 2010 |
| Cost-benefit analysis of vaccination against four preventable diseases in older adults: Impact of an aging population J Carrico, SE Talbird, EM La, S Poston, JE Poirrier, JK DeMartino, ... Vaccine 39 (36), 5187-5197, 2021 | 18 | 2021 |
| Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naive adults with HIV infection in the United States AJ Brogan, SE Talbird, C Cohen Value in Health 14 (5), 657-664, 2011 | 17 | 2011 |
| A steady-state, population-based model to estimate the direct and indirect effects of pneumococcal vaccines SE Talbird, AS Ismaila, TN Taylor Vaccine 28, G3-G13, 2010 | 17 | 2010 |
| Categorization of methods used in cost–effectiveness analyses of vaccination programs based on outcomes from dynamic transmission models J Mauskopf, S Talbird, B Standaert Expert review of pharmacoeconomics & outcomes research 12 (3), 357-371, 2012 | 14 | 2012 |
| US cost effectiveness of darunavir/ritonavir 600/100mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN trial A Brogan, J Mauskopf, SE Talbird, E Smets Pharmacoeconomics 28, 129-146, 2010 | 14 | 2010 |
| Value of the immunization program for children in the 2017 US birth cohort J Carrico, EM La, SE Talbird, YT Chen, MK Nyaku, C Carias, CE Mellott, ... Pediatrics 150 (3), 2022 | 12 | 2022 |
| Constrained optimization for the selection of influenza vaccines to maximize the population benefit: a demonstration project B Standaert, I Van Vlaenderen, LA Van Bellinghen, S Talbird, K Hicks, ... Applied Health Economics and Health Policy 18, 519-531, 2020 | 12 | 2020 |
| Treatment patterns and health care resource use in patients receiving multiple lines of therapy for metastatic squamous cell carcinoma of the head and neck in the United Kingdom EM La, EN Smyth, SE Talbird, L Li, JA Kaye, AB Lin, L Bowman European Journal of Cancer Care 27 (5), e12862, 2018 | 9 | 2018 |
Mawuli NyakuJanssen Pharmaceutical Companies of Johnson and JohnsonE-mail megerősítve itt: its.jnj.com
